+2,738.6%
ANET vs GSK
+97.4%
+2,641.2%
-52.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -11.6% | -0.1% | -11.5% | -11.6% |
| 7D | -15.0% | -5.3% | -9.7% | -14.1% |
| 30D | -9.1% | -3.7% | -5.4% | -8.4% |
| 3M | -8.8% | -7.3% | -1.5% | -7.5% |
| 6M | +19.3% | -4.2% | +23.6% | +19.2% |
| YTD | +27.9% | +0.9% | +27.1% | +25.4% |
| 1Y | +40.2% | +7.3% | +32.9% | +35.0% |
| 3Y | +211.4% | +52.7% | +158.6% | +158.6% |
| 5Y | +419.9% | +40.1% | +379.8% | +338.8% |
| All | +2,738.6% | +97.4% | +2,641.2% | +2,062.4% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling